Questions | Aim clearly described? | Main outcomes described in introduction or method? | patient’s characteristics clearly described? | Interventions clearly described? | Principal confounders clearly described | Main findings clearly described? | Estimates of random variability provided for main outcomes? | All adverse events reported? * | Characteristics of patients lost to follow up described? | p-value report for main outcome? | Subjects asked to participate representative of source population? | Subjects prepared to participate representative of source population? | Location and delivery of treatment was representative of source population? * | Study participants blinded to treatment? |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study/question number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
MA. Feger et al. 2016 [27] | 1 | 1 | 1 | Â | 1 | 1 | 1 | Â | Â | 1 | 0 | 1 | Â | Â |
L. Donovan et al. 2016 [17] | 1 | 1 | 1 | Â | 2 | 1 | 1 | Â | Â | 1 | 0 | 1 | Â | Â |
MA. Feger et al. 2018 [31] | 1 | 1 | 1 | Â | 2 | 1 | 1 | Â | Â | 1 | 0 | 1 | Â | Â |
DM. Torp 2019 [15] | 1 | 1 | 1 | Â | 2 | 1 | 1 | Â | Â | 1 | 0 | 1 | Â | Â |
AM. Ifarraguerri 2019 [16] | 1 | 1 | 1 | Â | 2 | 1 | 1 | Â | Â | 1 | 0 | 1 | Â | Â |
DC. Mueler. 2020 [25] | 1 | 1 | 1 | Â | 2 | 1 | 1 | Â | Â | 1 | 1 | 1 | Â | Â |
J. Jang et al. 2021 [30] | 1 | 1 | 1 | Â | 2 | 1 | 1 | Â | Â | 1 | 1 | 1 | Â | Â |
RM. Koldenhoven. 2021 [14] | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
DM. Torp. 2021 [6] | 1 | 1 | 1 | Â | 2 | 1 | 1 | Â | Â | 1 | 1 | 1 | Â | Â |
JL. Workman. 2021 [26] | 1 | 1 | 1 | Â | 1 | 1 | 1 | Â | Â | 1 | 0 | 0 | Â | Â |
KG. Migel 2021 [28] | 1 | 1 | 1 | Â | 2 | 1 | 1 | Â | Â | 1 | 1 | 1 | Â | Â |
KG. Migel 2021 [29] | 1 | 1 | 1 | Â | 2 | 1 | 1 | Â | Â | 1 | 1 | 1 | Â | Â |
DM. Torp. 2022 [3] | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
Percentage agreement reliability | 100% | 100% | 92% | Â | 96% | 100% | 96% | Â | Â | 100% | 96% | 92% | Â | Â |
Questions | Blinded outcome assessment | Any data dredging clearly described? * | Analysis adjusts for differing follow-up length? | Appropriate statistical test performed? | Compliance with interventions was reliable? * | Outcome measures were reliable and valid? | All participants recruited from the source population? * | All participants recruited over the same period of time? | Participants randomized treatment? | Allocation of treatment concealed from investigators and participants? | Adequate adjustment for confounding? | Losses to follow up taken into account? | Sufficient power to detect treatment effect at significance level of 0.05? | Â |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study/question number | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | Total |
MA. Feger et al. 2016 [27] | Â | 1 | Â | 1 | Â | 1 | 1 | 0 | Â | Â | 0 | Â | Â | 12 |
L. Donovan et al. 2016 [17] | Â | 1 | Â | 1 | Â | 1 | 1 | 0 | Â | Â | 0 | Â | Â | 13 |
MA. Feger et al. 2018 [31] | Â | 1 | Â | 1 | Â | 1 | 1 | 0 | Â | Â | 0 | Â | Â | 13 |
DM. Torp 2019 [15] | Â | 1 | Â | 1 | Â | 1 | 1 | 0 | Â | Â | 0 | Â | Â | 13 |
AM. Ifarraguerri 2019 [16] | Â | 1 | Â | 1 | Â | 1 | 1 | 0 | Â | Â | 0 | Â | Â | 13 |
DC. Mueler. 2020 [25] | Â | 1 | Â | 1 | Â | 1 | 0 | 1 | Â | Â | 0 | Â | Â | 14 |
J. Jang et al. 2021 [30] | Â | 1 | Â | 1 | Â | 1 | 1 | 0 | Â | Â | 0 | Â | Â | 15 |
RM. Koldenhoven. 2021 [14] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 23 |
DM. Torp. 2021 [6] | Â | 1 | Â | 1 | Â | 1 | 1 | 0 | Â | Â | 0 | Â | Â | 14 |
JL. Workman. 2021 [26] | Â | 1 | Â | 1 | Â | 1 | 1 | 0 | Â | Â | 0 | Â | Â | 11 |
KG. Migel 2021 [28] | Â | 1 | Â | 1 | Â | 1 | 1 | 0 | Â | Â | 0 | Â | Â | 14 |
KG. Migel 2021 [29] | Â | 1 | Â | 1 | Â | 1 | 1 | 1 | Â | Â | 0 | Â | Â | 15 |
DM. Torp. 2022 [3] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 24 |
Percentage agreement reliability | Â | 95% | Â | 100% | Â | 92% | 96% | 100% | Â | Â | 100% | Â | Â | Â |